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Abstract
Rationale Nicotine has been reported to produce both
anxiolytic and/or anxiogenic effects in humans and animals.
Objectives This study examined whether pretreatment with
nicotine would alter anxiety in a unique runway model of
approach–avoidance conflict.
Materials and methods Food-restricted rats were trained to
run a straight alley once a day to obtain food upon goal-box
entry. Beginning on trial 11, food reward was followed by a
series of five foot shocks (0.3–0.4 mA, 0.5 s) in the goal
box. Non-shocked control rats continued to run for food
only. The resulting association of the goal box with both a
positive (food) and negative (foot shock) stimulus produced
an approach–avoidance conflict (subjects exhibited “retreat
behaviors” in which they would approach the goal box,
stop, and then retreat back towards the start box). Once
retreats were established, their sensitivity to nicotine
pretreatment (0.0, 0.03, 0.045, 0.06, or 0.075 mg/kg, i.v.)
was compared to saline. In subsequent tests, the effects of
nicotine (0.06 or 0.03 mg/kg) were examined on spontane-
ous activity (locomotion) and center-square entries in an
open field (anxiety).
Results Doses of 0.06 and 0.075 mg/kg, but not lower
doses of nicotine, reduced the number of runway retreats,
and 0.06 mg/kg nicotine increased the number of open-field
center entries relative to saline. No effects on locomotion
were observed.
Conclusions Nicotine reduced approach–avoidance conflict
and increased the rats’ willingness to enter the center of an
open field, suggesting that the drug can produce anxiolytic
properties and that such effects may serve as an important
factor in the persistence of smoking behavior.
Keywords Nicotine . Runway . Straight alley .Motivation .
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Introduction
The maintenance of smoking behavior is generally thought
to be a consequence of the primary psychoactive ingredient
in tobacco smoke, i.e., nicotine (USDHHS 1988; Stolerman
and Shoaib 1991; Di Chiara 2000). Research on the
underlying neurobiological and behavioral factors respon-
sible for nicotine self-administration have typically concen-
trated on the drug’s positive reinforcing actions (e.g., Merlo
Pich et al. 1999; Di Chiara 2000; Mansvelder and McGehee
2002). However, convergent lines of evidence now suggest
an important role for the negative reinforcing properties of
nicotine, e.g., its stress-reducing actions (e.g., Picciotto et
al. 2002; Kassel et al. 2003; Baker et al. 2004; Feldner et al.
2007). For example, smoking behavior has been shown to
increase during stressful tasks (McKennell 1970; Pomerleau
and Pomerleau 1987; Perkins and Grobe 1992), and the
presence of stress has long been thought to increase the
risk of relapse in people who have stopped smoking
(Daughton et al. 1990). Related to the impact of stress on
smoking are suggestions that nicotine may in fact have
anxiolytic (anti-anxiety) properties (e.g., Picciotto et al. 2002;
Kassel et al. 2003). Tests of this notion, however, have yielded
inconsistent results. In some human self-report studies,
nicotine (but not nicotine-free tobacco) reduced both stress
and anxiety (Pomerleau et al. 1984; Gilbert et al. 1989;
Warburton and Mancuso 1998); however, in other studies, it
Psychopharmacology (2009) 204:541–549
DOI 10.1007/s00213-009-1486-7
A. Cohen : R. W. Young :M. A. Velazquez :M. Groysman :
K. Noorbehesht :O. M. Ben-Shahar :A. Ettenberg (*)
Behavioral Pharmacology Laboratory, Department of Psychology,
University of California,
Santa Barbara, CA 93106-9660, USA
e-mail: ettenberg@psych.ucsb.edu
had no such effect (Perkins et al. 1994; Herbert et al. 2001),
and others have even reported that nicotine produced elevated
levels of anxiety and negative affect (Newhouse et al. 1990;
Foulds et al. 1997). Adding to the complexity of this issue is
the fact that increased anxiety is a common symptom of
smoking cessation (e.g., Hughes et al. 1991; Tate et al. 1993);
hence, in the addicted smoker, the calming effects of nicotine
consumption may represent the temporary relief of withdrawal
symptoms (Parrott 2003) as opposed to an independent
anxiolytic action.
Animal studies have also yielded somewhat inconsistent
results when nicotine is delivered acutely to naïve subjects.
For example, in research employing the elevated plus maze
or the social interaction test, low doses of nicotine (0.05–
0.4 mg/kg, s.c. or i.p.) have been reported to have
anxiolytic properties (e.g., Brioni et al. 1993; File et al.
1998; Irvine et al. 1999; Cheeta et al. 2001), while higher
doses were demonstrated to produce anxiogenic effects
(e.g., File et al. 1998; Ouagazzal et al. 1999; Cheeta et al.
2001; Balerio et al. 2006). Yet, others have reported
anxiogenic actions of nicotine at doses as low as 1.0 mg/
kg, i.p. (e.g., Biala and Budzynska 2006; Biala and Kruk
2008). Moreover, nicotine has rarely been examined in the
more prototypical behavioral screens for anxiolytic agents
(i.e., approach–avoidance conflict tests). In the Vogel et al.
(1971) or the Geller–Seifter test (Geller et al. 1962), an
ongoing appetitive response (lever pressing for food or
licking a spout for water) is reliably suppressed upon
presentation of an aversive stimulus (e.g., mild shock)
paired with reinforcer delivery. Drugs that effectively
reduce this behavioral suppression are presumed to have
anti-anxiety properties and in fact have proven to be
effective anxiolytics in the human clinical population
(e.g., Houser 1978; McCloskey et al. 1987; Vaidya et al.
2005). It was therefore of interest to assess the anxiolytic
properties of nicotine in two procedurally different test
paradigms, i.e., an operant runway model of approach–
avoidance conflict and an open-field test that assesses the
animal’s unconditioned fear of open spaces.
Previous work in our laboratory has demonstrated that
food-deprived rats running a straight alley for food
reinforcement will exhibit “conflict” about entering the
goal box if the presentation of food is followed by aversive
foot shock (Geist and Ettenberg 1997). In such studies, the
dependent measure is not how much time it takes the
animal to traverse the alley (i.e., run time) but rather
the occurrence of approach–avoidance conflict that results
from concurrent positive and negative associations that
subjects have about goal-box entry. As originally suggested
by Miller (1944), this conflict can be operationally defined
by the frequency with which the animal approaches but
then moves away from the goal box. We quantify this
conflict through the measurement of “retreat behaviors,”
i.e., the number of times that an animal approaches the goal
box, stops at the entry point, and then turns and retreats
back toward the start box (e.g., Geist and Ettenberg 1997).
In addition to food+shock experiments, retreat behaviors
have also been shown to occur in animals running for drug
reinforcers known to have mixed positive+negative con-
sequences (e.g., cocaine; Ettenberg and Geist 1991, 1993;
Geist and Ettenberg 1997; Guzman and Ettenberg 2004).
Additionally, pretreatment with anxiolytic drugs dose-
dependently reduce retreat frequency in the runway, e.g.,
diazepam (Ettenberg and Geist 1991; Geist and Ettenberg
1997), alcohol (Knackstedt and Ettenberg 2005), heroin
(Guzman and Ettenberg 2004), and buspirone, a partial 5-
HT(1A) agonist (Ettenberg and Bernardi 2006).
As indicated above, nicotine self-administration is
thought to involve both positive and negative reinforcing
properties. We have previously reported (Cohen and
Ettenberg 2007) that animals will run an alley to earn i.v.
injections of nicotine upon goal-box entry (i.e., positive
reinforcement). In the current study, the effects of nicotine
on approach–avoidance conflict were assessed in rats
running for food paired with mild foot shock—a test of
the drug’s putative anxiolytic properties. Since there is no a
priori reason to assume that the effective dose in the runway
conflict test will be comparable to that required to sustain
runway self-administration, the current study included one
dose that supported runway self-administration (0.03 mg/kg,
i.v.), another that did not (0.06 mg/kg), and additional doses
that bracketed these two (i.e., 0.045 and 0.075 mg/kg). The
intent was to determine whether or not i.v. nicotine doses
shown to have different effects in a positive reinforcement
test would produce a similar profile in an approach–
avoidance conflict test. Finally, to aid in the interpretation
of the resulting data set, two additional tests were conducted:
(a) To assess for possible non-specific psychomotor actions
of nicotine (e.g., Clarke and Kumar 1983; Lee 1985;
Dwoskin et al. 1999; Miller et al. 2003; Neugebauer et al.
2006), its effects on spontaneous locomotor activity were
examined and (b) to ensure the validity of the runway
approach–avoidance test, the effects of nicotine were also
assessed in an open-field apparatus where anxiolytic drugs
have been shown to reduce a rat’s reluctance to enter the
central open “unprotected” regions of a novel environment
(e.g., Montgomery 1955; Prut and Belzung 2003).
Materials and methods
Subjects
Male Sprague–Dawley rats (300–350 g) from Charles River
Laboratories (Wilmington, MA, USA) were individually
housed in a temperature-controlled vivarium environment
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with food and water available ad libitum. Each animal was
handled for 10 min daily for 1 week to minimize the effects
of handling stress. The animals’ care and all experimental
procedures were reviewed and approved by the University
of California at Santa Barbara’s Institutional Animal Care
and Use Committee for compliance with the National
Institutes of Health Guide for the Care and Use of
Laboratory Animals (1996).
Surgery
The surgical procedures used here were precisely as described
previously (e.g., see Cohen and Ettenberg 2007). Briefly,
anesthesia was induced by inhalation of isoflurane gas (4%
for induction; 1.5–2.5% for maintenance) during which an
i.v. jugular catheter (PE20) was implanted in each rat.
During surgery, atropine (0.02 mg kg−1/0.05 ml, i.m.) was
injected to prevent respiratory congestion, and the non-opiate
analgesic, flunixin meglumine (Benamine, 2 mg kg−1/0.4 ml,
s.c.) was provided for post-surgical pain. The open end of
the catheter was passed s.c. to a threaded cannula (item
313G; Plastics One, Roanoke, VA, USA) exited through a
small opening on the animal’s back where it was secured in
place with the use of Mersilene mesh. Following surgery, the
antibiotic ticarcillin disodium and clavulantate potassium
(Timentin; 50 mg in 0.25 ml of 0.9% physiological saline,
i.v.) was injected i.v. followed by 0.1 ml of heparin (66 IU/
ml) to maintain catheter patency. Heparin and Timentin
injections were repeated once each day for 1 week, after
which a reduced dose of 10 mg Timentin (in 0.1 ml) was
injected daily throughout the rest of the experiment. The
patency of catheters was confirmed once a week by
assessing the loss of the righting reflex following a 1-mg
i.v. injection of the fast-acting barbiturate sodium methohex-
ital (Brevital; 1.0 mg dissolved in 0.1 ml nanopure water).
Food restriction
A restricted feeding protocol (approximately 15–20 g of
food/day) was initiated 7–10 days after surgery to gradually
reduce each rat’s body weight to 90% of free-feeding
values. Weights were then adjusted upwards each week in
recognition of the normal growth pattern of male rats over
time. All experimental trials were conducted between 0900
and 1400 hours each day and daily food rations were
provided 1–3 h after each runway session.
Drugs
(−)-Nicotine hydrogen tartrate salt (Sigma, St Louis, MO,
USA) was dissolved in a solution of 0.9% physiological
saline whose pH was adjusted to 7.2–7.4 by the addition of
sodium hydroxide. On test day, rats were administrated
with 0.0, 0.03, 0.045, 0.06, or 0.075 mg/kg, i.v. nicotine
(doses refer to free base) in a volume of 0.1 ml delivered by
a syringe/infusion pump (Razel) over a 4-s interval.
Operant runway conflict test
Runway apparatus
Trials were conducted in two identical wooden straight
alley runways (160 cm L×12 cm W×44 cm H). A start box
and a goal box were located at opposite ends of the runway
(each 23 cm L×20 cm W×44 cm H). Both start and goal
boxes were separated from the alley by means of sliding
doors. The runway floor consisted of small-diameter steel
rods arranged perpendicular to the runway walls. A food
trough was located on the rear wall inside the goal box for
delivery of the food reinforcement (45 mg Noyes, pellets),
and the goal box floor was wired to a Med Associates ENV
414 Shocker for the delivery of foot shock. The subject’s
location within the apparatus was detected in real time by
13 pairs of infrared photodetector–emitter pairs embedded
in the walls and evenly spaced along the length of the
runway (5 cm above the floor). The output of the infrared
sensors was fed to a desktop PC running custom software
(Hamilton-Kinder, San Diego, CA, USA). The computer
also controlled the operation of the start/goal doors, the
syringe pump, and data collection. The primary dependent
measure in this work, as in previous studies of this kind (e.g.,
Knackstedt and Ettenberg 2005; Ettenberg and Bernardi
2006), was the number of retreat behaviors occurring on
each trial prior to goal-box entry—an index that reflects the
intensity of the subject’s approach–avoidance conflict on a
given trial. A “retreat” was operationally defined as a stop
in forward locomotion followed by a return towards the
start box of a distance equivalent to at least two infrared
detectors (i.e., 30-cm distance); in practice, however, we
observed that once an animal stops and turns away from the
goal box, it invariably retreats all the way back to the start
box. In addition to retreat frequency, we also measured each
animal’s run time on every trial (the time to enter the goal
box once a rat had left the start box). Since run times would
be expected to change somewhat as a function of changes
in retreat behaviors (i.e., rats that exhibit more back and
forth behavior in the alley will obviously take longer to
enter the goal box than rats that exhibit fewer retreats; see
discussion by Ettenberg and Geist 1991), we expected this
measure to somewhat mirror any observed changes in
retreats that might be produced by nicotine.
Runway procedure
Phase 1: food training All rats were trained to traverse the
runway for food reinforcement over a 10-day period during
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which each animal experienced a single trial per day. Each rat
was placed into the start box for 10 s after which the start box
door opened and the animal was permitted to travel the length
of the alley and enter the goal box. The detection of the animal
in the goal box (by infrared sensors) signaled the computer to
close the goal door, after which ten 45-mg food pellets were
immediately delivered into the food trough. Rats were
provided 3 min to consume the food after which they
were returned to their home cages. On the occasional trial
when an animal did not enter the goal box within 15 min, it
was gently maneuvered into the goal box by the experimenter.
Phase 2: food+shock training Beginning on the 11th day
of runway testing, the delivery of the food reinforcer was
followed 1.5 min later by a series of five 0.5-s foot shocks
(0.3–0.4 mA in intensity and delivered one per second).
After 1.5 min upon termination of the foot shock, the rat
was removed from the goal box and returned to its home
cage. Testing continued in this manner—one trial per day—
until a given subject met a stable performance criterion of at
least three retreats per day on three out of four consecutive
days (requiring between 14 and 28 days/trials for different
animals). Once this criterion was reached for a given
subject, it was randomly assigned to one of the three
nicotine dose conditions (see below) and tested in phase 3
of the experiment. An additional group of rats served as
non-shock controls and continued to earn food (without
foot shock) throughout the second phase of the experiment.
Phase 3: nicotine challenge Once a rat had reached criterion
performance in phase 2 (i.e., exhibited stable levels of
approach–avoidance retreats over trials), it underwent a 2-
day test procedure. On the first day, each animal was
pretreated with a single 4-s i.v. injection of 0.1 ml 0.9%
physiological saline 10 min prior to a single food+shock
runway trial. This provided a baseline against which a
subsequent nicotine challenge could be compared. Note that
three animals did not exhibit the minimum three retreats on
baseline day and hence were removed from the study, the
logic being that there needed to be sufficient “conflict” on the
baseline trial against which to assess the effects of nicotine.
On the next day, each rat was pretreated 10 min prior to
runway testing with one of five doses of i.v. nicotine: 0.0 (n=
8), 0.03 (n=7), 0.045 (n=6), 0.06 (n=7), or 0.075 mg/kg
(n=7). The non-shocked control group (n=10) received
saline on the first day (baseline) and then a dose of 0.06 mg/
kg (test) prior to non-shocked food-reinforced runway trials.
Locomotor activity
An additional set of rats (n=24) was used to assess whether
or not changes in runway performance could be accounted
for by simple nonspecific changes in spontaneous locomo-
tor activity. The apparatus consisted of 12 identical
Hamilton-Kinder Plexiglas locomotor chambers (each
22 cm W×44 cm L×20 cm H). Intravenous catheterized
rats were individually placed into a chamber for 30 min
(baseline), removed and injected with one of three doses of
i.v. nicotine (0.0, 0.03, 0.06 mg/kg; n=8/group), and then
replaced (10 min post-injection) into the chambers for an
additional 30 min beginning 10 min post-injection. Note
that the treatment regimen intentionally included a dose that
effectively attenuated approach–avoidance conflict in the
runway (0.06 mg/kg) and another that did not (0.03 mg/kg).
The 10-min post-injection delay was instituted to ensure
comparability with the runway experiment. Infrared photo-
cell emitter–detector pairs lined the interior of the apparatus
and provided data to a PC running custom software
(“Motor Monitor” by Hamilton-Kinder) that converted the
beam interruptions into a measure of total distance traveled
(in centimeters).
Open-field test
Another set of i.v. catheterized rats (N=24) was randomly
assigned to one of three groups (corresponding to different
doses of i.v. nicotine) and assessed for their propensity to
enter the center squares of an open-field apparatus. The
apparatus consisted of two identical large square enclosures
(each 120 cm W×130 cm L×40 cm H) the floors of which
were each divided into sixteen 30-cm square regions: four
central squares and 12 squares along the periphery. Testing
was conducted under low light conditions (two 30-W red
lights). Each rat was injected with a single dose of i.v.
nicotine (0.0, 0.03, 0.06 mg/kg; six to eight rats/group) and
then placed into one of the corners of the apparatus starting
10 min post-injection. An observer (blind to the rat’s group
assignment) recorded the total number of entries into each
square in the apparatus over a single 10 min test session.
An entry was recorded when all four of the rat’s paws were
within a single square.
Results
Anti-conflict effects of nicotine in the runway conflict test
The effects of i.v. nicotine pretreatment on the retreat
behavior of animals running to a goal box associated with
both food and shock are depicted in Fig. 1. A two factor
(group × trial) analysis of variance (ANOVA) computed on
the retreat data revealed no main effect of group but did
yield a statistically significant effect of trial [F(1,30)=5.91,
p<0.05], confirming that when averaged across all groups,
the frequency of retreat behaviors on nicotine test days was
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different than that produced on baseline days. Of particular
relevance to the current study was a statistically significant
group × trial interaction [F(4,30)=2.8, p<0.05] indicating
that the change in behavior from baseline to test differed for
the five treatment groups. Indeed, as can be clearly seen in
Fig. 1, only the three highest doses of nicotine reduced
retreat behaviors on test day relative to baseline. Post hoc
analyses (simple one-tailed repeated measures t tests)
confirmed that retreats exhibited by the 0.06 and
0.075 mg/kg groups were reliably lower on test day
compared to baseline (p<0.01 and 0.05 respectively), while
the 0.045 group failed to reach statistical significance
(p>0.05).
The run times of nicotine-treated animals mirrored the
effects observed on retreats, although these changes
approached but did not reach statistical significance. On
test day, rats treated with 0.0, 0.03, 0.045, 0.06, or
0.075 mg/kg nicotine, respectively, entered the goal box
in 418.8±125.6, 276.7±74.6, 345.4±129.4, 110.5±32.9,
and 288.6±109.1 s. Thus, the animals with the fastest run
times (the 0.06 group) also made the fewest retreats, while
the animals in the two slowest groups (the 0.0 and 0.03
groups) made the most retreats on test day. Additionally, as
was the case with retreats, the only groups to demonstrate
shorter run times on test day relative to baseline were the
0.06 and 0.075 mg/kg groups. Note that we have not
included in the figure the data from non-shock control
subjects (n=10) running only for food reinforcement since
these animals exhibited no retreat behaviors either in the
presence or absence of 0.06 mg/kg, i.v. nicotine. Addition-
ally, the run times of these subjects did not significantly
differ between baseline (8.47±3.46) and test (7.59±2.56)
trials and were thus not reduced by nicotine pretreatment.
Locomotor activity
Figure 2 depicts the mean (±SEM) locomotor activity
(distance traveled) of each group during the pre-injection
baseline and following treatment with 0.0, 0.03, or 0.06 mg/
kg nicotine, i.v. Separate two-factor (group × time) ANOVAs
were computed on the pre-injection and post-injection data
shown in the figure. Both ANOVAs revealed statistically
significant effects of time [pre-injection: F(5,105)=2.52, p<
0.05; post-injection: F(5,105)=26.96, p<0.01], confirming
that on average, animals tended to slow their locomotion as
time progressed (a common pattern in locomotor activity
studies as the animals habituate to the test environment). The
effect of “time” was particularly pronounced during the post-
injection period where an initial “spike” in activity was
undoubtedly a consequence of the disruption (and resulting
arousal) caused by the removal of the animals and
administration of the i.v. injections. There were, however,
no group differences in locomotor activity nor a group ×
time interaction either before or after i.v. injections. Hence,
acute i.v. nicotine at the doses examined did not alter the
unconditioned spontaneous locomotion of treated animals.
Open-field test
While nicotine had no significant effect on the absolute
number of squares entered in the open field, the proportion
of total entries that rats made into the center squares was
reliably increased in the high- but not the low-dose group.
Fig. 1 Mean (+SEM) effects of nicotine on the total number of
retreats emitted by rats running a straight alley for food+foot shock.
Each of the five dose conditions were conducted in different groups of
subjects tested first on a non-treatment baseline (white bars) followed
by a test day (dark bars) in which their designated treatment (0.0,
0.03, 0.045, 0.06, or 0.075 mg/kg, i.v.) was administered 10 min prior
to testing. Retreats were reliably lower on test day compared to
baseline for the two high dose groups; **p<0.01, *p<0.05
Fig. 2 Mean (+SEM) locomotor activity for three groups of rats
during the 30 min prior to and the 30 min after injection with one of
three doses of i.v. nicotine (0.0, 0.03, or 0.06 mg/kg). The data are
expressed as “distance traveled” in centimeters during each 5-min
period. The vertical dotted line represents the point at which the
animals were removed, injected, and then replaced into the locomotor
activity apparatus 10 min later
Psychopharmacology (2009) 204:541–549 545
The mean (±SEM) total number of squares entered by the
0.0, 0.03, and 0.06 dose/groups were, respectively, 138.38±
12.8, 144.44±9.87, and 132.71±10.65 (one-factor indepen-
dent group ANOVA, p>0.05). Entries into the center
squares of the open field (expressed as a proportion of
total entries) are depicted in Fig. 3. A one-factor ANOVA
computed on those data revealed a statistically significant
group difference [F(2,21)=3.604, p<0.05], with Bonferroni
post hoc tests confirming that the 0.06 mg/kg group
performed differently (exhibited a greater proportion of
center entries) than both the 0.03- and 0.0-mg/kg groups
(p<0.05).
Discussion
The aim of the present study was to investigate the putative
anxiolytic effects of i.v. nicotine using a runway conflict
procedure. Food-restricted rats running a straight alley for
food+foot shock approached the goal box normally but then
hesitated about entering and tended to retreat back toward
the start box. This same behavioral paradigm was first
employed by Miller (1944) who described the animals’
behavioral ambivalence about goal-box entry as a form of
approach–avoidance conflict. More recently, Geist and
Ettenberg (1997) substantiated this conclusion by objec-
tively counting the frequency of retreat behaviors in the
alley and then demonstrating that these behaviors could be
dose-dependently attenuated by administration of the
anxiolytic agent, diazepam. In the current study, pretreat-
ment with 0.06 and 0.075 but not 0.03 or 0.045 mg/kg, i.v.
nicotine similarly reduced the number of retreats in rats
running toward a goal box associated with both food and
foot shock (see Fig. 1). This is not meant to suggest that
nicotine and diazepam have equivalent anxiolytic potency.
Indeed, while diazepam reduced both retreats and run times
in our earlier study (Geist and Ettenberg 1997), the effect of
nicotine on run time in the current study did not reach
statistical significance (p=0.098). Nevertheless, the sub-
jects’ pattern of responding in the runway remains
consistent with the hypothesis that nicotine can act to
reduce approach–avoidance conflict and hence may have
anxiolytic actions. Such actions could, of course, account
for some of the increases in self-administration that occur in
human smokers during stressful or high anxiety contexts
(McKennell 1970; Pomerleau and Pomerleau 1987; Perkins
and Grobe 1992) and related reports among smokers that
the drug helps individuals relax or feel calmer during
periods of stress or anxiety (Pomerleau et al. 1984; Gilbert
et al. 1989; Nichter et al. 1997).
Given the rate-independent nature of retreats (i.e., treat-
ments that simply slow or activate the animal would not in
and of themselves be expected to alter stop-and-retreat
behaviors), it is difficult to account for the nicotine-induced
changes in runway retreat behavior by non-specific psy-
chomotor actions of the drug. Indeed, 0.03 and 0.06 mg/kg,
i.v. nicotine (i.e., a dose that had no impact on retreat
behaviors and another that reliably reduced retreat frequen-
cy) neither increased spontaneous locomotion (Fig. 2) nor
altered the absolute number of squares crossed in an open-
field test. Additionally, while 0.06 mg/kg, i.v. nicotine
significantly reduced the number of retreats in rats
receiving food+shock, it did not affect the run times of
the non-shocked control group. While such findings would
appear to contradict the common classification of nicotine
as a psychomotor stimulant, in point of fact, the conditions
under which nicotine produces increases in unconditioned
locomotion are complex and variable. For example, some
studies have reported that acute nicotine causes an initial
suppression of activity followed subsequently by a stimu-
latory effect (Clarke and Kumar 1983; Ksir 1994; Miller et
al. 2001; Neugebauer et al. 2006), while other studies using
comparable nicotine doses have demonstrated a stimulatory
effect without a preceding suppressive phase (Tessari et al.
2004), or no effect at all (Shram et al. 2006). Additionally,
of the handful of studies that have employed an i.v. route of
administration (using doses similar to those employed in
the current research), one reported increased locomotion in
female rats (Samaha et al. 2005), two studies observed no
significant effects in male rats (Booze et al. 1999; Harrod et
al. 2004), and one described a modest decrease in activity
during the first few minutes post-injection (Cao et al. 2007).
This inconsistency in the published findings motivated us
to directly assess the locomotor effects of nicotine using the
two intermediate doses employed in the runway (i.e., 0.03
and 0.06 mg/kg, i.v.) and using the same post-injection time
frame (testing 10 min after nicotine administration). As
indicated above, we found no changes in nicotine-induced
Fig. 3 Open-field performance during a 10-min test for three groups
of rats pretreated with differing doses of i.v. nicotine. The data
represent group mean (+SEM) center-square entries expressed as a
percentage of total squares entered. *0.06-mg/kg group was statisti-
cally different from each of the other two groups (p<0.05)
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spontaneous unconditioned locomotion that could account
for the drug’s putative anti-conflict effects in the runway.
Consistent with the view that the 0.06-mg/kg, i.v. dose
of nicotine had anxiolytic actions in the runway was the
demonstration that it increased the willingness of treated
animals to enter into the center region of a novel open field
(Fig. 3). When placed into novel open fields, rats normally
exhibit thigmotaxis—i.e., a strong tendency to remain close
to the walls of the apparatus—an effect that is thought to
reflect an inherent fear of open unprotected spaces (Walsh
and Cummins 1976; Treit and Fundytus 1988; Prut and
Belzung 2003). Drugs that reduce anxiety in humans (e.g.,
anxiolytics) increase the proportion of center entries relative
to total entries (e.g., Montgomery 1955; Prut and Belzung
2003), as did the 0.06-mg/kg (but not the 0.03 mg/kg) dose
of nicotine in the current study. Thus, when taken together,
the results of the runway and open-field tests strongly
support the contention that acute nicotine administration
can have statistically reliable anxiolytic actions in labora-
tory animals and that such actions are not restricted to drug-
dependent animals in which the nicotine is merely reducing
the anxiety and stress associated with the onset of
withdrawal (e.g., see Parrott 2003).
The current results are of course consistent with those of
prior studies reporting anxiolytic effects of non-i.v. nicotine
(e.g., Brioni et al. 1993; Irvine et al. 1999; Cao et al. 2007),
while remaining in contrast to those reports suggesting
neutral or even anxiogenic effects of the drug (e.g.,
Morrison 1969; Glowa 1986; Balerio et al. 2006; Biala
and Budzynska 2006). This should not be particularly
surprising given the differences in the drug doses, routes of
administration, and experimental procedures between the
various studies. Indeed, in the earliest work on nicotine,
Goldberg and Spealman (1983) demonstrated that the same
doses of nicotine that were self-administered in one
experiment could serve as punishments and suppress lever
pressing under a fixed-ratio schedule of food presentation.
While we cannot therefore offer an explanation that would
account for the discrepancies in all of these published
reports, we do note two important and relatively unique
features of the current work: First, unlike the vast majority
of such studies, we have employed an i.v. route of drug
administration rather than applying the nicotine s.c. or i.p.
Our intent was to effectively model the relatively fast
delivery of nicotine that occurs with human smokers and to
use a route of administration that delivers a reliable and
constant dose of nicotine across animals. Subcutaneous and
i.p. routes of administration are methodologically easy to
conduct but produce highly variable and relative slow rates
of drug absorption that necessarily weaken the comparabil-
ity to the human condition. Second, unlike the majority of
previous animal studies of nicotine’s putative anxiolytic
effects (i.e., those employing the social interaction test or
elevated plus maze), the current runway conflict test uses a
methodology that is much more akin to the prototypical
behavioral screens for anxiolytic agents, such as the Vogel
test or the Geller–Seifter test. In such tests, the animals’
responding for a positive stimulus (e.g., food) is altered by
contingent presentation of a negative stimulus (shock), the
effects of which can be reversed by pretreatment with
anxiolytic agents (Houser 1978; McCloskey et al. 1987;
Vaidya et al. 2005). To our knowledge, the current results
are the first to demonstrate an anxiolytic effect of i.v.
nicotine using this type of approach–avoidance conflict test.
Together, the data from the current three experiments
strengthen the view that the motivation to seek nicotine is
derived from its ability to produce not only positive but also
negative reinforcement (via the drug’s anxiolytic actions).
The doses employed in this study were derived from our
previous work where animals exhibited faster running over
trials for goal-box entry that was reinforced by i.v.
administration of a single injection of 0.03 mg/kg nicotine
each day/trial (Cohen and Ettenberg 2007). This same dose
has also been reported to support lever press i.v. self-
administration in other studies (Corrigall and Coen 1989;
Donny et al. 1995; Watkins et al. 1999; De noble and Mele
2006). We note, however, that 0.03 mg/kg, i.v. nicotine was
ineffective in producing anxiolytic effects in the current
conflict test and that the larger 0.06-mg/kg dose which was
effective in the current study did not support reliable
runway self-administration performance in our prior study.
It would seem then that the positive and negative reinforc-
ing actions of the drug may require different dosing
regimens and hence may be related to dissociable actions
of nicotine within the nervous system. In this context,
individual differences in the acquisition, rate, and preferred
dose of nicotine self-administration may be accounted for
in part by the underlying motivation of the user and
whether the drug is being ingested primarily for its positive
or negatively reinforcing nature.
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